Significant data integrity violations were found at the Zhejiang facility of NingBo Huize Commodity Co., according to a warning letter FDA sent to the company on Aug. 2, 2019. According to FDA, during the inspection, which occurred from March 18 22, 2019, the company s quality staff admittedOriginal Article
You may also like
FDA Approves SpringWorks Therapeutics Treatment for...
ADVANCEMENTS IN GLP-1 ANALOG FORMULATION DEVELOPMENT:...
Axplora Announces €50 Million Investment in GLP-1...
Drug Digest: Advances in Small-Molecule Manufacturing
Navigating Drug Development: The Critical Role of...
MMS Acquires Exploristics and Its Flagship Modeling...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.